Developer docs
API playgroundTry for free, no card

Search company profiles

Ellume

Full company profile

uuid0003utu

Namestring
Ellume
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Ellume is a private, for-profit flu diagnostics company headquartered in East Brisbane, Australia, founded in 2010 by Sean Parsons, who continues to serve as Founder and CEO. The company develops diagnostic products in the influenza testing category, an area that requires regulatory clearance (FDA, TGA, CE) and operates within a clinically validated medical-device framework.

The company operates at a small commercial scale with 51-100 employees and has raised a single disclosed funding round of $5,000,000 in June 2019 (investors and lead investor unspecified in the available data). The website domain ellumehealth.com signals a health-focused commercial brand. No products, pricing, channel partners, customer logos, or revenue figures are detailed in the input data, and the most recent scrape of the corporate domain returned unrelated content rather than product or pipeline information, indicating a significant primary-source data gap.

The business model is not directly disclosed; as a flu diagnostics company, plausible revenue mechanics include B2B sales to pharmacies, clinics, employers, and government health agencies, and/or direct-to-consumer retail distribution. No go-to-market specifics, contract structures, or pricing tiers are evidenced in the available data, so the revenue model is characterized as assumed rather than confirmed.

Short descriptiontext

Ellume is a private flu diagnostics company founded in 2010 and headquartered in East Brisbane, Australia, developing regulated diagnostic products under founder and CEO Sean Parsons.

Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEast Brisbane, Australia
HQ citystring
East Brisbane
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
flu diagnostics, rapid antigen tests, diagnostic medical devices, respiratory diagnostics, at-home testing
Industry3 codes
PRIMARYHLAJABAE
Outbreak Investigation & Incident Management (EOC/ICS)
Healthcare & Life Sciences/Public Health, Government & Regulators/Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYBPAIAJAA
Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYHLAKAGAA
General Infectious Disease
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
Product category
In-Vitro Diagnostics
No data
Cost components5 values
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ellume is a flu diagnostics company that develops and manufactures diagnostic products for the detection of influenza. The company operates as a for-profit private entity headquartered in East Brisbane, Australia, with a workforce of 51-100 employees, and was founded in 2010. Specific product SKUs and detailed feature sets are not enumerated in the available source material.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Flu diagnostics products
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1LumiraDx
TypeDirect peer
Description

LumiraDx develops connected point-of-care diagnostic platforms with a respiratory menu (flu, COVID, RSV, Strep). Comparable to Ellume on technology approach and product breadth.

2Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's rapid diagnostics arm (Binax NOW, ID NOW) is the dominant player in point-of-care and at-home respiratory testing, including flu. Direct overlap with Ellume's core market.

TypeDirect peer
Description

QuidelOrtho (formerly Quidel) markets Sofia rapid antigen tests for flu, COVID, and RSV. Closest comparable in product format, customer channel, and regulatory pathway.

TypeBroad incumbent
Description

BD's Veritor System is a major rapid respiratory testing platform used in clinics and pharmacies. Competes head-to-head with Ellume in the professional POC flu-testing segment.

5Cue Health
TypeDirect peer
Description

Cue Health produces a connected molecular diagnostic platform for at-home and professional respiratory testing. Closest digital, connected-test competitor to Ellume.

TypeBroad incumbent
Description

Roche offers the cobas Liat PCR system and rapid antigen tests for influenza. A large, well-capitalized incumbent with overlapping respiratory testing offerings.

TypeBroad incumbent
Description

QIAGEN provides QIAstat-Dx multiplex respiratory panels and sample-prep kits, competing with single-pathogen rapid tests like Ellume's by offering broad pathogen detection.

TypeBroad incumbent
Description

BioFire's FilmArray multiplex PCR panels are the gold standard for respiratory pathogen testing. Represents the higher-sensitivity, lab-based alternative to Ellume's rapid test.

TypeBroad incumbent
Description

Hologic's Panther and Aptima molecular systems, along with rapid antigen products, place it in the broader respiratory diagnostics competitive set.

TypeEmerging player
Description

OraSure develops rapid diagnostic tests including at-home sample collection and infectious disease products. Comparable as a smaller specialty diagnostics player with overlapping infectious-disease focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ellume

In-Vitro Diagnosticsellumehealth.com

Ellume is a private flu diagnostics company founded in 2010 and headquartered in East Brisbane, Australia, developing regulated diagnostic products under founder and CEO Sean Parsons.

What Ellume does

Ellume is a private, for-profit flu diagnostics company headquartered in East Brisbane, Australia, founded in 2010 by Sean Parsons, who continues to serve as Founder and CEO. The company develops diagnostic products in the influenza testing category, an area that requires regulatory clearance (FDA, TGA, CE) and operates within a clinically validated medical-device framework.

The company operates at a small commercial scale with 51-100 employees and has raised a single disclosed funding round of $5,000,000 in June 2019 (investors and lead investor unspecified in the available data). The website domain ellumehealth.com signals a health-focused commercial brand. No products, pricing, channel partners, customer logos, or revenue figures are detailed in the input data, and the most recent scrape of the corporate domain returned unrelated content rather than product or pipeline information, indicating a significant primary-source data gap.

The business model is not directly disclosed; as a flu diagnostics company, plausible revenue mechanics include B2B sales to pharmacies, clinics, employers, and government health agencies, and/or direct-to-consumer retail distribution. No go-to-market specifics, contract structures, or pricing tiers are evidenced in the available data, so the revenue model is characterized as assumed rather than confirmed.

Ellume firmographics

Firmographics
Name
Ellume
Website
https://ellumehealth.com
Company type
Private
Founded year
2010
Headcount range
51–100 employees
Short description
Ellume is a private flu diagnostics company founded in 2010 and headquartered in East Brisbane, Australia, developing regulated diagnostic products under founder and CEO Sean Parsons.
Ownership category
akta.pro rank

Ellume industry classification

Industry
Product category
In-Vitro Diagnostics
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
akta.pro industry
PRIMARYHLAJABAE
Outbreak Investigation & Incident Management (EOC/ICS)
Healthcare & Life Sciences/Public Health, Government & Regulators/Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYBPAIAJAA
Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYHLAKAGAA
General Infectious Disease

Keywords

  • Flu diagnostics
  • Rapid antigen tests
  • Diagnostic medical devices
  • Respiratory diagnostics
  • At-home testing

Where Ellume is headquartered

Location

Headquarters

HQ city
East Brisbane
HQ country
Australia
HQ region
Oceania

Markets served

Ellume business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Ellume product offering

Product offering

Core offering

Ellume is a flu diagnostics company that develops and manufactures diagnostic products for the detection of influenza. The company operates as a for-profit private entity headquartered in East Brisbane, Australia, with a workforce of 51-100 employees, and was founded in 2010. Specific product SKUs and detailed feature sets are not enumerated in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

  • Flu diagnostics products

Companies that use Ellume

Customer profile

Ideal customer profiles1 record

Ellume technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Ellume partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights2 records

Ellume competitors and assessment

Company assessment

Direct peers

  • LumiraDx: LumiraDx develops connected point-of-care diagnostic platforms with a respiratory menu (flu, COVID, RSV, Strep). Comparable to Ellume on technology approach and product breadth.
  • QuidelOrtho Corporation: QuidelOrtho (formerly Quidel) markets Sofia rapid antigen tests for flu, COVID, and RSV. Closest comparable in product format, customer channel, and regulatory pathway.
  • Cue Health: Cue Health produces a connected molecular diagnostic platform for at-home and professional respiratory testing. Closest digital, connected-test competitor to Ellume.

Broad incumbents

  • Abbott Diagnostics: Abbott's rapid diagnostics arm (Binax NOW, ID NOW) is the dominant player in point-of-care and at-home respiratory testing, including flu. Direct overlap with Ellume's core market.
  • Becton, Dickinson and Company (BD): BD's Veritor System is a major rapid respiratory testing platform used in clinics and pharmacies. Competes head-to-head with Ellume in the professional POC flu-testing segment.
  • Roche Diagnostics: Roche offers the cobas Liat PCR system and rapid antigen tests for influenza. A large, well-capitalized incumbent with overlapping respiratory testing offerings.
  • QIAGEN: QIAGEN provides QIAstat-Dx multiplex respiratory panels and sample-prep kits, competing with single-pathogen rapid tests like Ellume's by offering broad pathogen detection.
  • bioMérieux (BioFire Diagnostics): BioFire's FilmArray multiplex PCR panels are the gold standard for respiratory pathogen testing. Represents the higher-sensitivity, lab-based alternative to Ellume's rapid test.
  • Hologic: Hologic's Panther and Aptima molecular systems, along with rapid antigen products, place it in the broader respiratory diagnostics competitive set.

Emerging players

  • OraSure Technologies: OraSure develops rapid diagnostic tests including at-home sample collection and infectious disease products. Comparable as a smaller specialty diagnostics player with overlapping infectious-disease focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Ellume financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ellume leadership team

Management profile

Number of profiles

Profiles1 record

Ellume funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ellume M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ellume

What does Ellume do?

Ellume is a flu diagnostics company that develops and manufactures diagnostic products for the detection of influenza. The company operates as a for-profit private entity headquartered in East Brisbane, Australia, with a workforce of 51-100 employees, and was founded in 2010. Specific product SKUs and detailed feature sets are not enumerated in the available source material.

When was Ellume founded?

Ellume was founded in 2010. It employs 51 to 100 people.

Where is Ellume based?

Ellume is headquartered in East Brisbane, Australia, in the Oceania region.

Who are Ellume's main competitors?

Direct peers on record are LumiraDx, QuidelOrtho Corporation and Cue Health. Broad incumbents are Abbott Diagnostics, Becton, Dickinson and Company (BD), Roche Diagnostics, QIAGEN, bioMérieux (BioFire Diagnostics) and Hologic. OraSure Technologies is listed as an emerging player.

Does Ellume have an API?

No public API is recorded for Ellume.

What industry is Ellume in?

Ellume's product category is In-Vitro Diagnostics. Its primary akta.pro industry code is HLAJABAE, Outbreak Investigation & Incident Management (EOC/ICS), with a secondary code of BPAIAJAA, Disease Surveillance, Epidemiology & Outbreak Response. Its NAICS code is 339113.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BloombergCovid Test Maker Once Crucial to US Response Set to Liquidate After Failed SaleEllume Ltd., the Australian company that secured the first US clearance for its at-home Covid-19 test kit, is winding down after its sale to Hough Consolidated Pty Ltd. fell through. Hough had agreed to buy the company in December for $38 million (A$56 million), but the deal collapsed after repeated deadline extensions.Australian Financial ReviewFTI hauls in bankers for Ellume sale, makes six point pitchFTI Consulting launched a two-stage auction for biotech Ellume Ltd, with expressions of interest due this week, indicative bids on November 7, and binding offers on November 28. The sale process is set to take seven weeks.ABCBrisbane biotech firm Ellume puts Australian arm into administrationEllume's Australian arm entered voluntary administration, with a creditor meeting scheduled later this month. The US business remains unaffected. The company had previously recalled 190,000 of 3.5 million tests due to false positives, but the recall's role is unclear.The Sydney Morning HeraldRapid testing start-up Ellume enters voluntary administrationEllume, a Brisbane-based rapid testing firm, has put its Australian arm into voluntary administration, with administrators John Park and Joanne Dunne appointed. The company reported an $87.8 million loss in 2021, up from $17 million in 2020, and its US entity continues trading. Creditors will meet in mid-September.PR NewswireELLUME COVID-19 HOME TEST NOW AVAILABLE THROUGH COVID.GOV/TESTS FOR BLIND AND LOW-VISION PEOPLEEllume has made its COVID-19 Home Test available at no cost to Americans who are blind or have low vision through a new White House initiative on covid.gov/tests. The test, developed by the digital diagnostics company, features audio step-by-step instructions and fully digital results accessible via smartphone screen readers. Each order includes twelve rapid antigen tests with free shipping, and the tests are being manufactured at Ellume's 215,000 square foot facility in Frederick, Maryland.PR NewswireELLUME OFFICIALLY OPENS PRODUCTION FACILITY IN FREDERICK, MARYLANDDigital diagnostics company Ellume officially opened its new 215,000 square foot production facility in Frederick, Maryland on March 31, 2022, with the capacity to produce approximately 15 million COVID-19 Home Tests per month. The facility, supported by a federal investment of more than $230 million, will initially bring 200 jobs and up to 1,500 jobs when operating at full capacity. The opening was attended by Maryland Governor Larry Hogan and other officials, representing Ellume's first U.S.-based manufacturing facility.JMIR PreprintsDiagnostic Accuracy of an At-Home, Rapid Self-test for Influenza: Prospective Comparative Accuracy StudyA prospective comparative accuracy study in the Greater Seattle area enrolled 605 participants who completed an at-home influenza rapid diagnostic test (Ellume) and mailed a reference swab for qRT-PCR testing. The RDT showed overall sensitivity of 61% and specificity of 95%, with sensitivity falling to 58% when testing occurred after 72 hours of symptom onset. Researchers found no link between lower sensitivity and illness severity.National Center for Biotechnology InformationDiagnostic Accuracy of an At-Home, Rapid Self-test for Influenza: Prospective Comparative Accuracy StudyA study evaluated the diagnostic accuracy of the Ellume at-home influenza rapid test among individuals with acute respiratory illness in the United States. The test demonstrated a sensitivity of 61% and specificity of 95%, showing comparable performance to clinical settings but with reduced sensitivity when used more than 72 hours after symptom onset. Researchers concluded that home tests may serve as a valuable tool for managing influenza despite false-negative results occurring later in the infection course.YahooAt-home COVID-19 tests can be hard to find — but these FDA-authorized options are still in stockAt-home COVID-19 tests are hard to find but several FDA-authorized options remain in stock. Rapid tests like BinaxNOW, Ellume, and QuickVue have varying accuracy, with BinaxNOW detecting 84.6% of positive cases. The article advises keeping a kit on hand.PR NewswireNEXT GENERATION TB TEST DEVELOPED WITH ELLUME TECHNOLOGY RECEIVES APPROVAL FROM KEY GLOBAL REVIEW PANEL FOR USE IN MORE THAN 100 LOW-RESOURCE, HIGH BURDEN COUNTRIESEllume and QIAGEN announced that their joint tuberculosis diagnostic test, QIAreach QuantiFERON-TB, has received approval from the Global Fund's Expert Review Panel for Diagnostics. This approval enables the product to be distributed to public health programs in over 100 low-resource countries with high TB burdens through Global Fund and UNITAID resources. The development supports the World Health Organization's End TB Strategy by improving access to effective diagnosis in regions with limited laboratory infrastructure.